REGEN-COV shown to reduce risk of COVID-19–related hospitalization or death from any cause

The phase 1-2 clinical trials conducted using REGEN-COV had shown promising therapeutic benefits in COVID-19 outpatients. Its effect was further investigated in the present phase 3 clinical trial, the findings of which have been published in the “The New England Journal of Medicine”.

Generated by Feedzy